Evidence map›Paper›PMID 39358780›Full record

Observational studyAlzheimer's research & therapy2024

Public perceptions related to healthcare preparedness to anti-amyloid therapies for Alzheimer's Disease in Japan.

Kenichiro Sato, Yoshiki Niimi, Ryoko Ihara, Atsushi Iwata, Kazushi Suzuki, Kiyotaka Nemoto, Tetsuaki Arai, Shinji Higashi, Ataru Igarashi, Kensaku Kasuga and 2 more

Abstract readObservational Study
In one paragraph

Observational study in Alzheimer's research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kenichiro SatoDepartment of Neuropathology, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Yoshiki NiimiUnit for Early and Exploratory Clinical Development, The University of Tokyo Hospital, Hongo 7-3-1, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Ryoko IharaDepartment of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Sakaecho 35-2, Itabashi-Ku, Tokyo, 173-0015, Japan.
Atsushi IwataDepartment of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Sakaecho 35-2, Itabashi-Ku, Tokyo, 173-0015, Japan.
Kazushi SuzukiDivision of Neurology, Internal Medicine, National Defense Medical College, Namiki 3-2, Tokorozawa-Shi, Saitama, 359-8513, Japan.
Kiyotaka NemotoDepartment of Psychiatry, Institute of Medicine, University of Tsukuba, Tennodai 1-1-1, Tsukuba-Shi, Ibaraki, 305-8575, Japan.
Tetsuaki AraiDepartment of Psychiatry, Institute of Medicine, University of Tsukuba, Tennodai 1-1-1, Tsukuba-Shi, Ibaraki, 305-8575, Japan.
Shinji HigashiDepartment of Psychiatry, Ibaraki Medical Center, Tokyo Medical University, Ami-Machi Chuo 3-20-1, Inashiki-Gun, Ibaraki, 300-0395, Japan.
Ataru IgarashiDepartment of Public Health, Yokohama City University School of Medicine, Fukuura 3-9, Kanazawa-Ku, Yokohama-Shi, Kanagawa, 236-0004, Japan.
Kensaku KasugaDepartment of Molecular Genetics, Brain Research Institute, Niigata University, Asahimachidori 1-757, Chuo-Ku, Niigata-Shi, Niigata, 951-8585, Japan.
Shuichi AwataIntegrated Research Initiative for Living Well With Dementia, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Sakaecho 35-2, Itabashi-Ku, Tokyo, 173-0015, Japan.
Takeshi IwatsuboDepartment of Neuropathology, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-Ku, Tokyo, 113-8655, Japan. iwatsubo@m.u-tokyo.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe approval of lecanemab, an anti-amyloid therapy for Alzheimer's disease (AD), necessitates addressing healthcare preparedness for disease-modifying treatment (DMT) to ensure appropriate, safe, and sustainable drug administration. Understanding public perceptions on this matter is crucial. We aimed to assess discrepancies and similarities in the perceptions of Japanese trial-ready cohort study ('J-TRC webstudy') participants and clinical specialists in the fields of dementia treatment and radiology, concerning affairs related to challenges in DMT preparedness.

methodsThis was a cross-sectional prospective observational study conducted in November-December 2023. The J-TRC webstudy participants were invited to participate in an online survey using Google Forms, and clinical specialists were invited to complete a mail-based survey. Main questionnaire items had been designed to be common in both surveys, and their responses were analyzed for participant attributes, interests, attitudes, expectations, and concerns about DMTs without specifying lecanemab.

resultsResponses were obtained from n = 2,050 J-TRC webstudy participants and n = 1,518 clinical specialists. Compared to specialists, more J-TRC respondents perceived the eligible proportion for DMT as smaller (59.1% versus 30.7%), perceived the eligible severity for DMT as more limited (58.0% versus 24.5%), and perceived the efficacy of DMT as slightly more encouraging (29.3% versus 34.8%). In terms of treatment prioritization, both J-TRC respondents and specialist respondents exhibited similar levels of acceptance for prioritizing patients to treat: e.g., approximately two-thirds endorsed patient prioritization under hypothetical resource constraints or other reasons. A medical rationale emerged as the most compelling reason for acceptance of patient prioritization across the surveys. In contrast, the need to address vulnerable populations was the reason that led to the least acceptance of prioritization, followed by economic considerations.

conclusionsOur findings offer valuable insights into the discrepancies in knowledge and perception between patients and healthcare providers. This could enhance the delivery of patient information in clinical settings and inform the discussion surrounding patient prioritization strategies.

Indexed as

Alzheimer DiseaseAdultAgedAntibodies, Monoclonal, HumanizedCross-Sectional StudiesFemaleHealth Knowledge, Attitudes, PracticeHumansJapanMaleMiddle AgedPerceptionProspective StudiesPublic OpinionSurveys and QuestionnairesAntibodies, Monoclonal, HumanizedDisease-modifying therapyOnline surveyPatient prioritizationPublic perceptionsTrial-ready cohort

Identifiers

PMID39358780
PMCPMC11448067

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.